Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 236 participants.

Also called NCT01410383

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 236 participants (enrolled count) (from the registry)
Sponsor
Karo Bio AB (from the registry)
Registry
  • NCT NCT01410383
Other papers using this trial's data
  • Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study The lancet. Diabetes & endocrinology, 2014-06 DOI, PubMed 24731671

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01410383. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2013-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Acronym
AKKA
Condition
Heterozygous Familial Hypercholesterolaemia
Intervention (Drug)
Placebo
Intervention (Drug)
Eprotirome
Intervention (Drug)
Eprotirome
Lead sponsor
Karo Bio AB (class: industry)

Record details

Record id
cardio:ct-nct01410383
Content hash
242bf41379465422a12d621fb6579350f1388d5cebde618d351d9484906769e3